膀胱尿路上皮癌组织中miR-372-5p、CDH1的表达水平及其临床意义

李红波; 李月兵

doi:10.13201/j.issn.1001-1420.2021.08.002

膀胱尿路上皮癌组织中miR-372-5p、CDH1的表达水平及其临床意义

李红波^,,
李月兵

- 南通大学附属如皋医院江苏省如皋市人民医院泌尿外科(江苏如皋, 226500)

详细信息

通讯作者: 李红波,E-mail:obf805@163.com

中图分类号: R737.14

收稿日期: 2020-12-22

Expression and clinical significance of miR-372-5p and CDH1 in bladder urothelial carcinoma

LI Hongbo^,,
LI Yuebing

- Department of Urology, Affiliated Rugao Hospital of Nantong University, Rugao People's Hospital, Rugao, Jiangsu, 226500, China

More Information

Corresponding author: LI Hongbo, E-mail: obf805@163.com

Received Date: 22 December 2020

摘要

摘要: 目的:探讨微小RNA-372-5p(miR-372-5p)、E-钙黏蛋白(CDH1)表达与膀胱尿路上皮癌患者预后的关系。方法:选取2014年7月—2015年9月于本院确诊的94例膀胱尿路上皮癌患者肿瘤组织作为膀胱癌组,选取其癌旁正常组织作为对照组。采用实时荧光定量PCR(qRT-PCR)法检测miR-372-5p表达水平,免疫组织化学法检测CDH1蛋白表达,Ualcan数据库检索CDH1在膀胱尿路上皮癌中的表达;Kaplan-Meier法分析膀胱尿路上皮癌患者肿瘤组织miR-372-5p、CDH1表达与预后的关系;多因素Cox回归分析影响膀胱尿路上皮癌患者预后的因素。结果:Ualcan数据库中,膀胱尿路上皮癌肿瘤组织中CDH1水平高于正常膀胱组织(P＜0.05)。膀胱癌组miR-372-5p表达水平低于对照组,CDH1阳性表达率高于对照组(P＜0.05)。肿瘤大小＞3 cm、可见肌层浸润、组织学分级3级膀胱尿路上皮癌患者miR-372-5p低表达、CDH1阳性表达比例高于肿瘤大小≤3 cm、未见肌层浸润、组织学分级1、2级患者(P＜0.05)。miR-372-5p高表达膀胱尿路上皮癌患者5年生存率高于miR-372-5p低表达患者(88.89%vs. 67.35%,χ²=6.274,P＜0.05);CDH1阳性表达膀胱尿路上皮癌患者5年生存率低于CDH1阴性表达患者(70.00%vs. 91.18%,χ²=5.609,P＜0.05)。CDH1是影响膀胱尿路上皮癌患者预后死亡的独立危险因素(P＜0.05),miR-372-5p是影响膀胱尿路上皮癌患者预后死亡的保护因素(P＜0.05)。结论:膀胱尿路上皮癌患者肿瘤组织中miR-372-5p表达下调、CDH1表达上调,二者均与临床病理特征相关,且是患者预后的影响因素。
- 膀胱尿路上皮癌 /
- 微小RNA-372-5p /
- E-钙黏蛋白 /
- 临床病理特征 /
- 预后
Abstract: Objective: To investigate the relationship between the expression of microRNA-372-5 p(miR-372-5 p), E-cadherin(CDH1) and clinicopathological characteristics, prognosis of bladder urothelial carcinoma.Methods: From July 2014 to September 2015, tumor tissues of ninety-four patients with bladder urothelial carcinoma were selected as the bladder cancer group, and the adjacent normal tissues were selected as the control group. Real-time fluorescence quantitative PCR(qRT-PCR) was used to detect the expression level of miR-372-5 p, and immunohistochemistry was used to detect the expression of CDH1 protein. The expression of CDH1 in bladder urothelial carcinoma was retrieved using Ualcan database. Kaplan-Meier method was used to analyze the relationship between the expression of miR-372-5 p, CDH1 and prognosis in patients with bladder urothelial carcinoma. Multivariate Cox regression analysis was used to analyze the prognostic factors of bladder urothelial carcinoma.Results: In the Ualcan database, the level of CDH1 in bladder urothelial carcinoma was higher than that in normal bladder tissue(P＜0.05). The expression level of miR-372-5 p in bladder cancer group was lower than that in control group, and the positive expression rate of CDH1 was higher than that in control group(P＜0.05). The proportions of miR-372-5 p low expression and CDH1 positive expression in patients with tumor size＞3 cm, muscle layer infiltration and histological grade 3 were higher than those with tumor size ≤3 cm, without muscle layer infiltration and histological grade 1 and 2(P＜0.05). The 5-year survival rate of bladder urothelial carcinoma with high expression of miR-372-5 p was higher than that of patients with low expression of miR-372-5 p(88.89% vs. 67.35%,χ²=6.274, P＜0.05). The 5-year survival rate of patients with CDH1 positive expression was lower than that of patients with CDH1 negative expression(70.00% vs. 91.18%,χ²=5.609, P＜0.05). CDH1 was an independent risk factor for the prognostic death of patients with bladder urothelial carcinoma(P＜0.05), while miR-372-5 p was a protective factor(P＜0.05).Conclusion: The expression of miR-372-5 p is down-regulated and the expression of CDH1 is up-regulated in bladder urothelial carcinoma. Both of them are related to clinicopathological features and are the influencing factors of prognosis.
- bladder urothelial carcinoma /
- microRNA-372-5p /
- E-cadherin /
- clinicopathological features /
- prognosis

HTML全文

参考文献(14)

[1]	Nagai T,Okamura T,Yanase T,et al.Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients[J].Asian Pac J Cancer Prev,2019,20(4):1271-1273.
[2]	张涛,王志平.膀胱尿路上皮癌PD-1/PD-L抑制剂的治疗进展[J].海南医学院学报,2019,25(8):635-640.
[3]	Piao XM,Jeong P,Kim YH,et al.Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria[J].Int J Cancer,2019,144(2):380-388.
[4]	Cheng X,Chen J,Huang Z.miR-372 promotes breast cancer cell proliferation by directly targeting LATS2[J].Exp Ther Med,2018,15(3):2812-2817.
[5]	Godwin TD,Kelly ST,Brew TP,et al.E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation,dynamics and function[J].Gastric Cancer,2019,22(2):273-286.
[6]	陈莉,汪涌,祝广峰,等.2020年欧洲泌尿协会肌层浸润性膀胱癌诊断和治疗指南概要[J].现代泌尿外科杂志,2020,25(11):1025-1029.
[7]	Yang CD,Yuan WB,Yang X,et al.Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21,PTEN expression[J].Mol Cancer,2018,17(1):19-30.
[8]	Lee SH,Hu W,Matulay JT,et al.Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer[J].Cell,2018,173(2):515-528.e17.
[9]	Alvaeus J,Rosenblatt R,Johansson M,et al.Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer,after neoadjuvant chemotherapy and radical cystectomy[J].World J Urol,2020,38(9):2207-2213.
[10]	麦尔哈巴·阿不都热依木,潘燕.非编码RNA作为ceRNA在人癌症中的功能及机制[J].中国生物化学与分子生物学报,2020,36(8):895-902.
[11]	Wang Y,Li Z,Lin Q,et al.Highly Sensitive Detection of Bladder Cancer-Related miRNA in Urine Using Time-Gated Luminescent Biochip[J].ACS Sens,2019,4(8):2124-2130.
[12]	Kitagawa K,Shigemura K,Sung SY,et al.Possible correlation of sonic hedgehog signaling with epithelial-mesenchymal transition in muscle-invasive bladder cancer progression[J].J Cancer Res Clin Oncol,2019,145(9):2261-2271.
[13]	张伟,郭永连,李国灏,等.miR-372-3p在膀胱癌组织中的表达及其对膀胱癌细胞增殖、迁移与侵袭的影响[J].中国肿瘤生物治疗杂志,2018,25(1):45-50.
[14]	Wang MX,Qiu YF,Zhang R,et al.MEHP promotes the proliferation of oral cancer cells via down regulation of miR-27b-5p and miR-372-5p[J].Toxicol In Vitro,2019,58(1):35-41.